ClinicalTrials.gg
RecruitingNCT06873841CoBRaUpdated Jul 8, 2025

Cognitive-psychophysiological Treatment for Tics in Young People With Tourette's Syndrome With or Without Biofeedback

An interventional study of Cognitive psychophysiological and Cognitive psychophysiological and Biofeedback in Tourette Syndrome, Tics and Tourette Syndrome in Adolescence, sponsored by Université du Québec a Montréal. Recruiting at 1 site in Canada. Open to participants aged 14 Years to 21 Years. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Université du Québec a Montréal · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
14 Years to 21 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the effectiveness of CoPs therapy with or without the therapeutic component of biofeedback in treating tics in Tourette Syndrome with emerging young adults.

Hypotheses:

  1. The CoPs+Biofeedback treatment will improve the severity of tics (YGTSS) and the Clinical Global Impression, surpassing the clinical significance threshold of CoPs treatment alone.
  2. We expect that the identified variables (psychosocial, neurocognitive, biological) will predict the improvement of tics.

Researchers will compare if the biofeedback treatment will improve the severity of tics.

  • In the pre-test, participants will undergo two interviews, each lasting 3 hours. These interviews will assess (through a battery of tests) the severity of tics as well as the psychosocial, biological, and neurocognitive aspects of functioning. A general assessment of intelligence and executive functions will also be conducted.
  • They will next attend 10 to 12 therapy sessions, with or without biofeedback. (The biofeedback component is explained in more detail in the ''Study Design'' section).
  • The post-test follow-ups consist of two evaluations: one 3 months after the end of the treatment and the other 6 months after. The evaluation will be done using the same battery of tests as during the pre-test interview.
Read the detailed description

* The project explanations are in English for everyone's ease of understanding, but our study is conducted in French. *

02

Conditions studied

  • Tourette Syndrome
  • Tics
  • Tourette Syndrome in Adolescence

Keywords

  • CoPs
  • Biofeedback
  • cognitive-psychophysiological therapy
  • Tourette
  • Young adults
  • Tics
  • Treatment
03

In context

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

This study's planned enrollment of 150 is above the median of 36 across 183 interventional studies indexed under Tourette Syndrome.

Browse Tourette Syndrome studies →

Lead sponsor

Université du Québec a Montréal is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of TS or to experience bothersome tics;
  • Be aged 14 to 21 years inclusive at the start of therapy.

Exclusion criteria

Exclusion Criteria:

  • Present a sensorimotor impairment;
  • Have a diagnosis of intellectual disability (intelligence quotient below 75);
  • Alcohol or drug abuse;
  • A neurological issue (e.g., hemifacial spasms, Huntington's disease);
  • Change medication one month or less before step 1 and up to step 4 (last measurement time) without informing a member of the research team;
  • Simultaneously receive another intervention for tics (e.g., psychologist, massage therapist) without informing a research team member.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Cognitive-psychophysiological therapy (CoPs).

    Six therapeutic steps: 1) Awareness training; 2) Profile of high/low-risk situations for tics; 3) Muscular discrimination; 4) Reduction of sensorimotor activation and modification of action planning style; 5) Cognitive, metacognitive, and behavioral restructuring in high-risk tic situations; 6) Generalization and relapse prevention. The individual sessions last 80 minutes: 55 minutes of therapy, 20 minutes of active listening and 5 minutes for a computer activity. The active listening and activity are unrelated to the analyses but ensure that treatment modalities are equivalent in duration and use of a computer. Participants will be informed about the duration of the therapy (10 to 12 sessions weekly) and that its completion requires continuous attendance at the sessions. The program has been adapted for youth with a treatment guide containing examples and exercises tailored for better understanding. Adolescents aged 14 to 17 will receive this manual to support their comprehension.

    Behavioral: Cognitive psychophysiological

  • Experimental
    Cognitive-psychophysiological therapy (CoPs) combined with biofeedback exercises.

    After each 55-minute CoPs session (same protocol as arm 1), 25 minutes will be dedicated to biofeedback exercises (80 minutes total). This 25-minute period includes 2 minutes to record the baseline resting level, 15 minutes for the active biofeedback session, and 2 minutes for the second resting measurement. Active electromyographic (EMG) biofeedback will take the form of computer-generated graphs displayed on a screen at 2 meters (horizontal angle). Changes in muscle activity will cause the movement of a balance with a silvered ball; the graphical feedback of this stimulus is particularly effective in capturing the participant's attention and interactive engagement. The goal is to contract the arm muscle to keep the ball balanced for 5 minutes for each arm, then 5 minutes with both arms (15 minutes).

    Behavioral: Cognitive psychophysiological and Biofeedback

Interventions

  • BehavioralCognitive psychophysiological

    Focus on the processes influencing thoughts and behaviors underlying tics.

  • BehavioralCognitive psychophysiological and Biofeedback

    Biofeedback refers to visual exercises that help improve movement control.

06

What researchers measure

Primary outcomes

  1. Primary outcome

    The Yale Global Tic Severity Scale (YGTSS) provides an assessment of motor and vocal tics based on 5 dimensions: number, frequency, intensity, complexity, and interference. A subtotal of 50 is used to determine the severity of the tics. A separate scale assesses impairment, or the overall effect of tic disorders on daily functioning, with another subtotal of 50. In this study, only the tic severity score out of 50 will be used (comparable to other studies focusing on tics).

    Time frame: The YGTSS is administered trough the study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months))

Secondary outcomes

  1. Conners

    Psychosocial measures For ADHD symptoms, the Conners 3 (8-18 years) or Conners' Adult ADHD Rating Scales (CAARS)

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  2. CY-BOCS

    For OCD symptoms, the Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  3. STAI

    For anxiety symptoms, the State-Trait Anxiety Inventory (STAI).

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  4. Perfectionism Scale

    The adapted/inadapted Perfectionism Scale

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  5. Beck Depression Invetory

    For mood-related symptoms, the Beck Depression Inventory will be used.

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  6. STOP

    The Style of Planning Action (STOP)

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  7. Self-Esteem Inventory

    The short version of the Self-Esteem Inventory.

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  8. TS-Quality of Life Scale

    TS-Quality of Life Scale will also be used.

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  9. Perdue Pegboard Test

    The evaluation of fine motor dexterity using the Purdue Pegboard will determine the baseline equivalence between groups and test functional differences after treatment. The Finger-Tapping Test will be administered to assess speed and motor control.

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  10. Perceived Stress Scale (PSS-14)

    We will collect a hair sample to measure the cortisol levels of the participants: a 14-item Perceived Stress Scale (PSS-14) will be administered at the 4 time points of measurement.

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  11. Finger-Tapping Test

    The Finger-Tapping Test will be administered to assess speed and motor control.

    Time frame: Administered trough study completion, an average of 1 year (T1 pre, T2 post, T3 follow up (3 months), T4 follow up (6 months)).

  12. DKEFS CWIT

    Participants will be assessed with the 4 sections of the DKEFS CWIT: color naming, word reading, inhibition.

    Time frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).

  13. Brief Cannabis Consumption Questionnaire

    To attest the consumption of cannabis.

    Time frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).

Other outcomes

  1. SCID-5-RV130

    The Structured Clinical Interview for DSM-5 - Research (SCID-5-RV130) will allow for clinical screening of disorders that may present a differential or comorbid diagnosis with PTSD, which could impact treatment engagement or outcomes.

    Time frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).

  2. BASC-3-SRP131

    The Behavioral Assessment System, 3rd Edition - Self-Report of Personality (BASC-3-SRP131) will be administered to provide an overall profile of affect and behavior, complementing the SCID-5-RV.

    Time frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).

  3. Bem Sex Role

    Sex assigned at birth and gender identity will be assessed using the Bem Sex Role Inventory.

    Time frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).

  4. Wechsler

    General intelligence will be evaluated through subscales of the Wechsler Intelligence Scale for Children/Adults, depending on the participant's age (WAIS-IV, WISC-V: Vocabulary, Matrices).

    Time frame: Only in T1 (pre-test) , up to 4 weeks (first interview).

  5. BRIEF

    Executive functions will also be screened using the Brief Inventory of Executive Function (BRIEF), (version for ages 14-18 years or adults).

    Time frame: Only in T1 (pre-test) , up to 4 weeks ( first interview).

07

Study locations

1 of 1 sites recruiting
  • Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal, Hôpital Rivières-des-Prairies
    Montreal, Quebec H1E 1A4, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06873841
Lead sponsor
Université du Québec a Montréal
Collaborators
Ciusss de L'Est de l'Île de Montréal
Responsible party
Julie Leclerc (Full professor, psychology department, UQAM. Researcher & Mental Health Research Director, Centre intégré universitaire santé et services sociaux (CIUSSS) Nord-de-l'Île-de-Montréal. Associate Researcher, Institut Universitaire Santé Mentale de Montreal, Université du Québec a Montréal) — Principal investigator
First posted
Mar 13, 2025
Start date
Apr 15, 2025
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jul 8, 2025

Study contacts

Julie Leclerc, Psychology
Contact
leclerc.julie@uqam.ca
1-514-987-3000 ext. 5267
Audrey-Ann Lachance
Contact
audrey-ann.lachance.cnmtl@ssss.gouv.qc.ca
1-514-323-7260 ext. 2381
Julie Leclerc, Psychology
principal investigator · Université du Québec à Montréal- UQAM
Marc Lavoie, Psychology
study chair · Université TÉLUQ
Marie-France Marin, Psychology
study chair · Université du Québec à Montréal-UQAM

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion